Background: Diabetes mellitus (DM) complications are associated with ischemic injury. Angiogenesis is a therapeutic strategy for diabetic foot. The aim of this study was to investigate the possible angiogenic effect of low molecular weight fucoidan (LMWF) in diabetic peripheral arterial disease (PAD). Methods: Diabetic db/db mice and age-matched C57BL/6 mice underwent femoral artery ligation followed by LMWF (30, 60, 80 mg/kg per day, p.o.) or cilostazol (30 mg/kg/day, p.o.) treatment for 6 weeks. Endothelium-dependent vasodilation and blood flow of the hindlimb were measured. Histological and western blot analyses of CD34, vascular endothelial growth factor (VEGF), eNOS, and inflammatory factors in the gastrocnemius were performed. The effects of LMWF were confirmed in human umbilical vein endothelial cells (HUVEC). Results: Diabetic mice with ligation exhibited hindlimb ulceration, hydrosarca, and necrosis, increased expression of inflammatory factors, and decreased levels of VEGF and eNOS phosphorylation. Treatment with LMWF markedly ameliorated foot lesions, suppressed expression of inflammatory factors, and improved plantar perfusion by promoting endothelium-dependent vasodilation and revascularization in diabetic PAD mice. In high-glucose treated HUVEC, LMWF (40 μg/mL) reversed blunted endothelial cell proliferation, migration, and tube formation, and promoted eNOS phosphorylation and VEGF expression, whereas HUVEC pretreatment with 100 μmol/L N
Introduction
Diabetic patients are at high risk of endothelial dysfunction and vascular lesions because of multiple harmful stimuli, including hyperglycemia, hyperlipidemia, oxidative stress, and inflammation, that contribute significantly to diabetic vascular comlications.
1,2 Peripheral arterial disease (PAD) is characterized by chronic obstruction of the arterial blood supply because of the formation of atherosclerotic plaques or thrombi in the lower extremities, leading to critical limb ischemia. 3, 4 Severe hypoperfusion finally results in ischemic ulceration and gangrene in the feet, at which stage amputation may be the only option for many patients. 5 Although effective management for control of vascular risk factors has improved the treatment for diabetes, diabetic patients with PAD remain at high risk of high morbidity, disability, and mortality. In recent years, therapeutic angiogenesis by gene or cell therapy or surgical vessel reconstruction has yielded promising results for PAD in preclinical and early phase clinical studies. 6, 7 However, non-invasive therapies such as drugs are still the first choice and supplement invasive treatments to improve blood flow to ischemic tissues. 6 In previous studies we found that low molecular weight fucoidan (LMWF) from seaweed Laminaria japonica J.E. Areschoug has an antithrombotic effect without affecting coagulation, [8] [9] [10] and protects endothelial function in type 2 diabetic (T2D) rats. 8 Fucoidans have been shown to have a wide variety of biological activities, including antitumor, 11, 12 antiviral, 13 antiinflammatory, antioxidative, and antithrombotic actions. 10, [14] [15] [16] Recently, LMWF was shown to improve residual muscle blood flow and increase angiogenesis in a murine model of critical hindlimb ischemia. 17, 18 In addition, we previously demonstrated a protective effect of LMWF against endothelium lesion-induced hindlimb injury in Goto-Kakizaki (GK) rats, 19 a model of T2D with hyperglycemia but not obesity. However, the mechanism underlying this protection remains unknown. In the present study we used db/db mice, a classical animal model, to mimic the typical pathological features of human T2D, namely hyperglycemia, hyperlipidemia, obesity, endothelial dysfunction, and development of vascular complications, and investigated: (i) the in vivo therapeutic effects of LMWF on hindlimb blood flow and ischemic injury of the gastrocnemius muscle induced by ligation of the femoral artery; (ii) ex vivo effects of LMWF on endothelium-dependent vasodilation, as well as the expression of CD34, vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and inflammatory factors in the ischemic gastrocnemius; and (iii) in vitro effects of LMWF on endothelial cell migration, tube formation, eNOS phosphorylation and nitric oxide (NO) release in high glucose (HG)-treated human umbilical vein endothelial cells (HUVEC). The results show that LMWF effectively recovers blood flow by reversing the downregulation in eNOS function and VEGF expression, resulting in increased vasodilation and angiogenesis in the PAD model in diabetic mice.
Methods

Animals and surgery
Wild-type C57BL/6 (10-12 weeks old) and age-matched db/db mice were purchased from Peking University Health Science Center (Beijing, China). Mice were anesthetized and ischemia was induced in the left hindlimb by ligation of the left femoral artery, as described previously. 20 Briefly, the hindlimb was shaved and the entire left superficial femoral artery was ligated with 5-0 silk sutures, cut and excised with an electrical coagulator. The overlying skin was closed with 4-0 silk sutures.
All experimental procedures were approved by the Capital Medical University Animal Care and Use Committee (AEEI-2015-045). All studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals adopted by the Beijing Municipal People's Government and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. 21 Blood flow measurement Hindlimb blood flow was measured with a full-field laser perfusion imager (FLPI) system (moorFLPI; Moor Instruments, Axminster, UK), as described previously. 22 Before measurement, the optimum positions between the instrument probe and an animal's left and right legs were explored and then fixed for all measurements in the study. Mice were monitored by serial scanning of the surface blood flow of hindlimbs before occlusion and then immediately and 1, 3 and 6 weeks after surgery. Digital color-coded images were analyzed to quantify blood flow in the region from the knee joint to the toe. Mean perfusion values were calculated and the ratio of blood flow in the ischemic (left) to nonischemic (right) hindlimb was taken as the degree of blood flow block and compared between different treatments. Data collection in this way can avoid systematic variations in recordings at different times and instrument error.
After surgery, mice were randomly divided into seven groups: a normal group (C57BL/6 mice), a diabetes mellitus (DM) sham group (without femoral artery ligation), a DM model group (femoral artery ligation), three LMWF-treated groups (treatment with 30, 60 or 80 mg/kg LMWF), and a cilostazol (30 mg/kg)-treated group. The LMWF used in the present study (molecular mass~7000 Da) was supplied by the Institute of Oceanology, Chinese Academy of Sciences (Qingdao, China) and was dissolved in distilled water, as described previously. 10, 23 Cilostazol, a drug often used in PAD treatment because of its antiplatelet aggregation, vessel dilation, and vascular endothelium protective effects, 24 was purchased from Zhejiang Otsuka Pharmaceutical (Zhejiang, China). Drugs were administered intragastrically after surgery every day for 6 weeks in the treatment groups, with an equal volume of vehicle (water) administered to mice in the untreated groups.
Body weight and plasma glucose levels were measured once a week. Plasma glucose concentrations were measured using a glucometer (ACCU-CHEK Active; Roche Diagnostics, Mannheim, Germany). Blood pressure was monitored using a non-invasive CODA blood pressure monitoring system (Kent Scientific, Torrington, CT, USA). Plasma concentrations of NO, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured using ELISA kits (Jiancheng Bioengineering, Nanjing, China).
Grading of foot damage in diabetic PAD mice
To determine the progression and severity of lesions in ischemic feet, 4 weeks after surgery the ulceration, hydrosarca, and necrosis that are often observed in the occluded hindlimb were graded and classified as follows: Grade 1, normal; Grade 2, discoloration or rhagades; Grade 3, local ulceration; Grade 4, diffuse ulceration; Grade 5, total hydrosarca, necrosis, or defluxion.
25,26
Measurement of isolated thoracic artery tension
At the end of the 6-week period after surgery, thoracic aortas were quickly and carefully removed from normal and DM mice, and adhering tissue was cleaned off with special care in ice-cold Krebs'-Henseleit buffer, as described previously. 8 The isometric tension of the rings was measured using a force displacement transducer (159 928, Radnoti 8 Unit Tissue Organ Bath System; Radnoti, Monrovia, CA, USA) and recorded using a data-acquisition system (MP150; BIOPAC Systems, Goleta, CA, USA). Rings were equilibrated at a resting tension of 0.75 g. After contraction induced by 60 mM KCl, rings were washed three times with Krebs'-Henseleit buffer and allowed to equilibrate for another 60 min, after which rings were contracted with 1 μmol/L phenylephrine (PE). Once the contractile response had plateaued, 10 μmol/L acetylcholine (ACh) was added to the organ baths to determine maximum endothelial-dependent relaxation.
Histological analysis
To assess pathological changes in the gastrocnemius, at the end of the 6-week period after surgery, the mean surface area of each muscle was quantified in mice from different groups using Image-Pro Plus software 5.1 (Media Cybernetics, Bethesda, MD, USA), and is reported as a ratio of the mean surface area in the ischemic to non-ischemic limb. Appropriate sections of the gastrocnemius were prepared and stained with hematoxylin and eosin (HE). In addition, sections were stained immunohistochemically using anti-CD34 (Abcam, Cambridge, MA) or anti-VEGF antibodies (Santa Cruz, Dallas, TX, USA), according to the manufacturer's instructions. 27 Images were acquired using a KFBIO Digital Pathology System (Konfoong Biotech International, Zhejiang, China). To demonstrate tissue architecture and pathological changes, five independent fields were assessed for each sample and the area of vacuoles (>5-6 μm in diameter) was determined using ImagePro Plus 5.1, with data presented as the percentage vacuolated area. Similarly, the number and area of vessels in stained samples (HE, CD34, or VEGF) was analyzed using Image-Pro Plus 5.1.
Expression of inflammatory factors
Gastrocnemius protein lysates was collected to evaluate expression of inflammatory factors, including tumor necrosis factor-α (TNF-α), monocyte chemotactic protein-1 (MCP-1), and interleukin-6 (IL-6) using commercially available ELISA kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions.
Cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased from American Type Culture Collection (ATCC; Menassas, VA, USA). The HUVEC were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Corning, Brisbane, Qld, Australia) and 5.5 mmol/L glucose (normal glucose [NG]) in a 5% CO 2 incubator at 37 C for 48 h. Cells from passages 4-12 were used for all experiments. For HG stimulation, cells were treated with 25 mmol/L glucose for 48 h, with drugs added to the culture at the same time as HG. Dishes of HUVEC were randomly divided into six groups and treated (48 h) as follows: (i) NG; (ii) 25 mmol/L mannitol; (iii) HG; (iv) HG +20 μg/mL cilostazol; (v) HG+40 μg/mL LMWF; and
Western blot analysis
Tissues and cells were lysed in RIPA buffer and total protein was quantified using a BCA assay kit (Thermo Scientific, Waltham, MA, USA). Lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% nonfat milk or 5% bovine serum albumin, and then incubated with primary antibodies overnight at 4 C, followed by incubation with secondary antibodies for 1 h at room temperature after three washes with Tris-buffered saline solution containing Tween 20. The primary antibodies against eNOS, phosphorylated (p-) eNOS (Ser   1177   ) , CD34, VEGF, ICAM-1, IL-1β, α-tubulin, and β-actin, as well as all horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology. Immunoreactive bands were detected using the chemiluminescence FluorChem FC3 system (Protein Simple, San Jose, CA, USA). Relative luminescence intensity was analyzed using Quantity One software (BioRad Laboratories, Hercules, CA, USA).
Cell viability assay
Cell viability was evaluated using the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Briefly, HUVECs were plated at a density of 5 × 10 4 cells/well in 96-well plates. The cells were incubated in 100 μL NG medium (5.5 mmol/L glucose), HG (25 mmol/L glucose) or mannitol (25 mmol/L) as the osmotic control. In the HG+LMWF group, 40 μg/mL LMWF was added to the cells at the time of HG addition. After treatment with 20 μL MTT (5 mg/mL) for another 4 h, the solution was discarded and 150 μL dimethylsulfoxide (DMSO) was added to each well. Absorbance was determined at a wavelength of 490 nm using a microplate reader (SpectraMax M2; Molecular Devices, Sunnyvale, CA, USA). Cell viability in the different groups was calculated as follows:
Cell viability (%) = (OD treatment group − OD blank )/ (OD control group − OD blank ) × 100.
where OD is the optical density in the different groups.
Migration assay
The migration of HUVEC was estimated using the wound healing assay. Briefly, 2 × 10 4 cells/well were plated into six-well plates in HG (25 mmol/L), with or without LMWF (40 μg/mL) or cilostazol (20 μg/mL), in DMEM (Gibco, Grand Island, NY, USA) containing 1% fetal bovine serum. In each well, the HUVEC monolayer was scraped with a sterile pipette tip to generate a cell-free zone, with three scratches made. The non-migrating cells were removed from the filter by three washes with phosphate-buffered saline (PBS) and were incubated in DMEM at 37 C for 24-48 h. Photographs were taken using a microscope (Leica TCS SP2 Microsystems, Heidelberg, Germany). Migrated cells were then quantified using Image-Pro Plus 5.1.
Matrigel angiogenesis
To evaluate angiogenesis, HUVEC were plated at density of 2 × 10 4 cells/well and were incubated in DMEM in 96-well plates precoated with Matrigel. Tube formation was observed under an inverted light microscope 2 h after seeding. Five independent fields were assessed for each well and at least three wells were examined for each group. The mean number of tubes per magnified field was determined, and tube length was measured as the mean summed length of capillary-like structures in each field (at ×100) using Image-Pro Plus 5.1.
Statistical analysis
All data are presented as the mean AE SEM. The significance of differences between groups was determined by one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) post hoc multiple comparisons test using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was accepted at twosided P < 0.05.
Results
Effects of LMWF on plasma glucose, lipid, and NO profiles in db/db mice Fasting blood glucose concentrations, blood lipid profiles and plasma NO concentrations were evaluated in mice after the 6-week treatment period of drugs and compared with values in normal mice. As indicated in Table 1 , blood glucose concentrations, body weight, and blood lipids levels, including TC, TG, and LDL-C, were significantly higher in diabetic than normal mice, whereas HDL-C and plasma NO concentrations were appreciably lower. Administration of LMWF at doses of 30, 60 and 80 mg/kg per day markedly reversed these changes, except that high blood glucose concentrations in diabetic mice were unaltered. Similarly, cilostazol ameliorated the abnormities in blood lipids and NO, as reported previously. 28, 29 To evaluate the effects of LMWF on blood perfusion in diabetic mice, the FLPI system was used before occlusion and then again immediately and 1, 3 and 6 weeks after hindlimb surgery. Diabetic mice with hindlimb ischemia exhibited lower and slower blood flow recovery than Sham mice 6 weeks after surgery (50.35 AE 2.53% vs 100%, respectively; P < 0.01), whereas mice in both the LMWF-and cilostazol-treated groups showed much higher and faster blood flow recovery than vehicle-treated DM mice over the 1-to 6-week period of observation (Fig. 1a,b) . Blood flow recovery at the end of the 6-week period after surgery was 84.53 AE 9.46%, 93.60 AE 7.48% and 97.13 AE 9.77% in 30, 60 and 80 mg/kg LMWF-treated mice, respectively, compared with 96.41 AE 12.28% recovery in cilostazol-treated mice (P < 0.01 for all vs vehicletreated DM mice). In addition, diabetic mice with hindlimb ischemia exhibited severe ulceration and gangrene compared with those in the Sham group. The severity of hindlimb lesions was graded as described in the Methods (see Fig. 1c ). Like cilostazol, LMWF effectively improved the occurrence and severity of foot damage (Fig. 1d) .
As shown in Fig. 2a -c, compared with the nonischemic hindlimb, the ischemic hindlimb of db/db mice clearly developed muscle shrinkage, manifested as reductions in both the weight and area of the gastrocnemius. In HE-stained sections of the ischemic hindlimb, significant changes were seen in the architecture of the gastrocnemius, including blunted muscle fiber edges and the appearance of vacuolations (Fig. 2d) in sections from vehicle-treated diabetic mice (Model) compared with the Sham group. However, in both LMWFand cilostazol-treated mice, muscular vacuolation was reduced (Fig. 2e ) and there were sharper fiber edges compared with the Model mice (Fig. 2d) .
Effect of LMWF on expression of inflammatory factors
Ischemia and hypoxia can evoke inflammatory responses and substantially increase the expression of inflammatory factors, which further aggravate tissue injury. Thus, the anti-inflammatory effects of LMWF on ischemic gastrocnemius in db/db mice were examined. As shown in Fig. 3 , HE staining of ischemic hindlimb muscle showed damaged muscle fibers with inflammatory cell infiltration and increased expression of inflammatory cytokines, including IL-1β, ICAM-1, IL-6, MCP-1 and TNF-α, compared with gastrocnemius muscle from the hindlimb of mice in the Sham group. Administration of LMWF significantly inhibited these inflammatory responses to ischemia. Similar protective effects were also seen in cilostazol-treated mice.
Effect of LMWF on neovascularization in ischemic hindlimb of db/db mice
To understand how LMWF alleviates ischemic muscle injury, we first explored the possible effect of LMWF on neovascularization because it has been suggested that LMWF increases collateral vessel formation in murine models of critical hindlimb ischemia 17, 18 and diabetic hindlimb ischemia. 19 Thus, CD34-and VEGFpositive vessels were quantified using immunohistochemistry in ischemic tissues on week 6 after surgery. As shown in Fig. 4a-d Fig. 4e-h ). In addition, eNOS phosphorylation at Ser 1177 was upregulated by LMWF and cilostazol in diabetic PAD mice.
Protective effect of LMWF against diabetes-induced endothelial dysfunction
It is well accepted that abnormal eNOS plays an important role in endothelial dysfunction and lesions in diabetes, 2, 30 and endothelium-derived NO is primarily generated by activation of eNOS, particularly by its phosphorylation at Ser 1177 . 2, 30, 31 Thus, to determine the effect of LMWF on vessels, we further investigated eNOS function in diabetic mice by evaluating relaxation responses to ACh (10 μmol/L) in PE (1 μmol/L) precontracted aortic ring, as well as aortic p-eNOS (Ser 1177 ) and NO levels. As reported previously in GK diabetic rats, 8 natural relaxation and ACh-induced relaxation of PE-constricted aortic rings were much smaller in diabetic than normal mice (Fig. 5a) . Administration of LMWF dose-dependently improved the reduced aortic relaxations in diabetic mice. Cilostazol treatment also significantly improved vasodilation. In addition, levels of total eNOS and peNOS (Ser 1177 ) in the aorta and plasma NO concentrations, as determined by western blot analysis and ELISA, respectively, were significantly decreased in diabetic compared with normal mice ( Fig. 5b-d ; Table 1 ). However, these changes were dosedependently reversed in LMWF-treated diabetic mice, with almost complete recovery of p-eNOS (Ser 1177 ) found in the 60 mg/kg LMWF-treated group compared with untreated db/db mice. Cilostazol treatment also increased eNOS expression, eNOS phosphorylation, and NO production in diabetic PAD mice.
Effects of LMWF on HG-induced changes in eNOS function and expression in HUVEC
To further verify the effects of LMWF on eNOSassociated neovascularization, cultured HUVEC were challenged with HG (25 mmol/L) or same concentration of mannitol (25 mmol/L) as an osmotic control for 48 h in the presence or absence of LMWF (40 μg/mL), an effective concentration in endothelial cells, 8, 9 after which the phosphorylation of eNOS at Ser 1177 , NO production, and CD34 and VEGF expression were examined. The results showed that HG stimulation induced downregulation of eNOS phosphorylation at Ser 1177 and CD34 and VEGF expression compared with mannitol-treated cells, whereas LMWF administration resulted in marked recover in these HG-induced changes (Fig. 6a-e) . In addition, cell viability was determined in response to different treatments using the MTT assay. After exposure of HUVEC to HG, cell viability decreased significantly over the 48 h culture period. The addition of 40 μg/mL LMWF to HG significantly increased cell viability compared with HG alone (Fig. 6f ) .
Proangiogenic effect of LMWF in HUVEC
To further characterize the effects of LMWF on angiogenesis, we investigated the effects of LMWF and cilostazol on HUVEC function using the wound healing assay and tube formation. The results showed that HUVEC migration at 24 and 48 h was significantly decreased in the HG compared with NG and mannitol groups, and that this was reversed by LMWF or cilostazol treatment (Fig. 7a,b) . In addition, HG treatment significantly reduced tube formation after 48 h culture of HUVEC cells compared with the NG and mannitol groups, whereas LMWF and cilostazol reversed the inhibitory effects of HG on tube formation (Fig. 7c) . Pretreatment of cells with L-NAME (100 μmol/L), a specific inhibitor of eNOS, almost completely inhibited the effects of LMWF on HUVEC migration and tube formation (Fig. 7a-e) , indicating an important role of eNOS in LMWF-mediated HUVEC migration and tube formation. ]), and VEGF in the gastrocnemius in each group. Results were normalized against those in the Sham group, which was set to 1. t-eNOS, total eNOS. Data are the mean AE SEM (n = 6-13 animals per group). *P < 0.05, **P < 0.01 compared with the Sham group; † P < 0.05, † † P < 0.01 compared with the model group.
Discussion
It has been reported that LMWF promotes blood flow recovery in critical hindlimb ischemia and protects vasoendothelial function and tissues against chronic ischemic tissue injury. 8, [17] [18] [19] 32 However, the mechanism underlying these beneficial effects remains largely unknown. The results of the present study demonstrate that LMWF effectively protects against diabetic hindlimb ischemic injury. This effect is likely attributable to improved local blood flow perfusion (Fig. 1a) , which was due, at least in part, to vessel dilation and enhanced angiogenesis, as manifested by increased CD34-positive vascular density correlated with upregulated CD34 and VEGF expression and eNOS activation in the ischemic hindlimb of db/db mice (Figs 4-5 ) and HG-stimulated HUVEC (Figs 6-7) . In addition, the inhibitory effects of LMWF on platelet aggregation 19 and hypolipidemia (Table 1) are also beneficial to the ischemic hindlimb in diabetic animals.
It is accepted that the development of a collateral vessel network plays a critical role in recovery of tissue ischemia after vascular occlusion, and VEGF is the key regulator promoting the process of collateral vessel formation and stimulation of vascular endothelial cell recruitment, proliferation, and differentiation. 33, 34 Under diabetic conditions, VEGF expression is paradoxically increased in the retina, but decreased in peripheral tissues due to hypoxia. 35, 36 The findings of the present study regarding VEGF expression are consistent with previous reports that, in peripheral ischemic tissues of diabetic db/db mice, VEGF levels are further appreciably downregulated. 37 Accumulating evidence suggests that there is a reciprocal relationship between VEGF and NO in the endogenous regulation of endothelial integrity following arterial injury, in which arterial balloon injury results in endothelial cell disruption, thereby acutely reducing NO production, accompanied by VEGF stimulation. 38 The VEGF then further ) expression in the aorta. The results were normalized against those of the normal group, which were set to 1. DM, diabetes mellitus. Data are the mean AE SEM (n = 3-4 per group). *P < 0.05, **P < 0.01 compared with the normal group; † P < 0.05, † † P < 0.01 compared with the DM or Model group.
increases the production of NO by activating phosphatidylinositol 3-kinase and Akt phosphorylation, which then phosphorylate eNOS and increase eNOS activity. 39, 40 Endothelium-derived NO is also an important regulator of vascular function and plays a key role in the regulation of leukocyte adhesion to the endothelium, endothelial cell survival, angiogenesis, and inflammation. 41, 42 All the established cardiovascular risk factors, such as DM, hypercholesterolemia, hypertension, and smoking, have been suggested to decrease endothelial NO production, 43 which participates in the ischemic injuries of PAD. 44 Therefore, improvement in endothelial NO production represents a reasonable therapeutic strategy in the treatment of diabetic vascular complications. 45, 46 Phosphorylation of eNOS at Ser 1177 has been recognized as the most important residual site in eNOS activity. 29, 47 In the present study, LMWF administration significantly reversed the deficiency in VEGF generation and eNOS phosphorylation in ischemic hindlimb. In addition, LMWFstimulated neovascularization correlated with the increases in eNOS phosphorylation at Ser 1177 and VEGF expression. Importantly, the LMWF-induced improvement in endothelial cell migration and tube formation in HG-treated cells is in accordance with ]), CD34, and VEGF expression in cultured HUVEC. Results were normalized against the 25 mmol/L mannitol (Man)-treated group, which was set to 1. NG, normal glucose (5.5 mmol/L); HG + F, high glucose (25 mmol/L) plus 40 μg/mL LMWF. (c) Nitric oxide production and (f ) cell viability of HUVEC in the presence or absence of LMWF, as determined by ELISA or the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide assay, respectively. HUVEC with or without LMWF by MTT assay was measured. Data are the mean AE SEM (n = 3 per group). *P < 0.05, **P < 0.01 compared with the mannitol group; † P < 0.05, † † P < 0.01 compared with the HG group. the promotion of eNOS phosphorylation and VEGF expression, whereas inhibition of eNOS with a specific antagonist abolished the effects of LMWF (Fig. 7) . Because there is integration and cross-talk between the VEGF and eNOS pathways in angiogenesis, [38] [39] [40] 42 the results of the present study demonstrate that the therapeutic effect of LMWF in DM hindlimb ischemia is most likely mediated via activation of the eNOS/NO and VEGF pathways.
Inflammation has been implicated in both neovascularization and tissue damage via expression of cytokines and inflammation-associated angiogenic factors. 48 Many inflammatory factors, such as TNF-α, IL-1β, MCP-1, and ICAM-1, have been shown to exert deleterious effects on vascular inflammation and tissue injuries in ischemic regions after artery ligation. [49] [50] [51] There is no doubt that the best therapeutic approach requires the promotion of angiogenesis with inhibition of the inflammatory response due to invasive interference and increased blood flow. 6 Previous studies have demonstrated that LMWF has antioxidant and antiinflammatory activities.
14 In accordance, in the present study LMWF significantly suppressed inflammationassociated factors IL-1β, ICAM-1, IL-6, TNF-α, and MCP-1 (Fig. 3) , all of which are involved in the ischemic injury. [49] [50] [51] Thus, these findings provide the first evidence that LMWF may accomplish the clinical need for improving blood flow in ischemic tissues while avoiding detrimental inflammatory responses.
Cilostazol is an antiplatelet and antithrombotic vasodilator that has been used for the treatment of chronic PAD and the secondary prevention of brain infarction. 52, 53 Moreover, cilostazol has been shown to inhibit vascular smooth muscle cell proliferation and protect the vascular wall and endothelium function, thus improving peripheral blood flow. 22 With regard to adverse effects, cilostazol may have several serious side effects, such as diarrhea, dizziness, increased heart rate, and arrhythmia; 54 thus, the use of LMWF, which has similar beneficial effects but with much lower toxicity, 55 appears to be advantageous over the use of cilostazol for the treatment of PAD.
Together, the findings indicate that LMWF protects against ischemic injury in diabetic PAD most likely through angiogenesis and endothelium-dependent vasodilation. The upregulation of VEGF expression, eNOS phosphorylation, and NO production and inhibition of inflammatory responses are the basis for the therapeutic effects of LMWF. Therefore, the present study in db/db mice and the previous study in GK rats 19 demonstrate that LMWF is a candidate drug for the prevention and treatment of diabetic PAD, that LMWF shares similar beneficial effects with cilostazol and, as such, is an alternative choice for non-invasive revascularization treatment in diabetes subjects with PAD.
